The present review is focused on the role of diagnostic tomographic imaging such as computed tomography and magnetic resonance imaging to assess and predict tumor response to advanced medical treatments in metastatic renal cell carcinoma (RCC) patients. In this regard, antiangiogenic agents and immune checkpoint inhibitors (ICIs) have developed as advanced treatment options replacing the conventional therapy based on interferon-alpha and interleuchin-2 which had unfavorable toxicity profile and low response rates. In clinical practice, the imaging evaluation of treatment response in cancer patients is based on dimensional changes of tumor lesions in sequential scans; in particular, Response Evaluation Criteria in Solid Tumors (RECIST) have ...
Background: Response evaluation criteria in solid tumours (RECIST) is widely used to assess tumour r...
AbstractStudying early response to cancer treatment is significant for patient treatment stratificat...
Renal cell carcinoma (RCC) is the most frequent renal tumor and the majority of patients are diagnos...
AbstractTargeted therapies have considerably improved the prognosis of patients with metastatic rena...
CONTEXT: The introduction of targeted agents for the treatment of renal cell carcinoma (RCC) has res...
Targeted therapy is the treatment of choice in patients with metastatic renal cell cancer (mRCC) at ...
T-cell immunotherapy and molecular targeted therapies have become standard-of-care treatments for re...
Abstract Background Tyrosine kinase inhibitors are the first line standard of care for treatment of ...
BACKGROUND: CT imaging is widely used for response evaluation of immunotherapy in patients with adva...
As the most common neoplasm arising from the kidney, renal cell carcinoma (RCC) continues to have a ...
Objective: to compare the criteria for tumor response to targeted therapy and immunotherapy for meta...
Background: Response evaluation criteria in solid tumours (RECIST) is widely used to assess tumour r...
Abstract Response Evaluation Criteria in Solid Tumors (RECIST) is the gold standard for assessment o...
Zusammenfassung In der Radiologie stellen die Response Evaluation Criteria in Solid Tumors (RECIST 1...
PurposeLiver metastases from renal cell carcinoma (RCC) are not uncommon in the course of disease. H...
Background: Response evaluation criteria in solid tumours (RECIST) is widely used to assess tumour r...
AbstractStudying early response to cancer treatment is significant for patient treatment stratificat...
Renal cell carcinoma (RCC) is the most frequent renal tumor and the majority of patients are diagnos...
AbstractTargeted therapies have considerably improved the prognosis of patients with metastatic rena...
CONTEXT: The introduction of targeted agents for the treatment of renal cell carcinoma (RCC) has res...
Targeted therapy is the treatment of choice in patients with metastatic renal cell cancer (mRCC) at ...
T-cell immunotherapy and molecular targeted therapies have become standard-of-care treatments for re...
Abstract Background Tyrosine kinase inhibitors are the first line standard of care for treatment of ...
BACKGROUND: CT imaging is widely used for response evaluation of immunotherapy in patients with adva...
As the most common neoplasm arising from the kidney, renal cell carcinoma (RCC) continues to have a ...
Objective: to compare the criteria for tumor response to targeted therapy and immunotherapy for meta...
Background: Response evaluation criteria in solid tumours (RECIST) is widely used to assess tumour r...
Abstract Response Evaluation Criteria in Solid Tumors (RECIST) is the gold standard for assessment o...
Zusammenfassung In der Radiologie stellen die Response Evaluation Criteria in Solid Tumors (RECIST 1...
PurposeLiver metastases from renal cell carcinoma (RCC) are not uncommon in the course of disease. H...
Background: Response evaluation criteria in solid tumours (RECIST) is widely used to assess tumour r...
AbstractStudying early response to cancer treatment is significant for patient treatment stratificat...
Renal cell carcinoma (RCC) is the most frequent renal tumor and the majority of patients are diagnos...